• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.导管消融治疗心房颤动的研究需求和重点:来自美国国立心肺血液研究所虚拟研讨会的报告。
Circulation. 2020 Feb 11;141(6):482-492. doi: 10.1161/CIRCULATIONAHA.119.042706. Epub 2019 Nov 20.
2
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report.心房颤动二级预防的研究重点:美国国立心肺血液研究所虚拟研讨会报告
J Am Heart Assoc. 2021 Aug 17;10(16):e021566. doi: 10.1161/JAHA.121.021566. Epub 2021 Aug 5.
3
Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.推进心房颤动和心力衰竭之间复杂相互关系的研究:美国国家心肺血液研究所虚拟研讨会的报告。
Circulation. 2020 Jun 9;141(23):1915-1926. doi: 10.1161/CIRCULATIONAHA.119.045204. Epub 2020 Jun 8.
4
Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.心房颤动筛查的研究重点:来自美国国立心肺血液研究所虚拟研讨会的报告。
Circulation. 2021 Jan 26;143(4):372-388. doi: 10.1161/CIRCULATIONAHA.120.047633. Epub 2021 Jan 25.
5
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.心房颤动的预防:美国国立心肺血液研究所研讨会报告
Circulation. 2009 Feb 3;119(4):606-18. doi: 10.1161/CIRCULATIONAHA.108.825380.
6
Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control.心力衰竭合并心房颤动的管理:是时候实施消融控制了。
Curr Cardiol Rep. 2019 Feb 21;21(2):10. doi: 10.1007/s11886-019-1093-0.
7
Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.射血分数降低的心力衰竭患者中导管消融与房颤传统治疗的比较:一项随机对照试验的系统评价和荟萃分析
J Interv Card Electrophysiol. 2018 Oct;53(1):19-29. doi: 10.1007/s10840-018-0425-0. Epub 2018 Jul 31.
8
Hybrid thoracoscopic surgical and transvenous catheter ablation versus transvenous catheter ablation in persistent and longstanding persistent atrial fibrillation (HARTCAP-AF): study protocol for a randomized trial.杂交胸腔镜手术与经静脉导管消融治疗持续性和长期持续性心房颤动(HARTCAP-AF):一项随机试验的研究方案。
Trials. 2019 Jun 20;20(1):370. doi: 10.1186/s13063-019-3365-9.
9
Virtual ablation for atrial fibrillation in personalized in-silico three-dimensional left atrial modeling: comparison with clinical catheter ablation.个性化计算机模拟三维左心房模型中房颤的虚拟消融:与临床导管消融的比较
Prog Biophys Mol Biol. 2014 Sep;116(1):40-7. doi: 10.1016/j.pbiomolbio.2014.09.006. Epub 2014 Sep 28.
10
Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).美国社区医疗实践中房颤的导管消融术——房颤更优知情治疗结局注册研究(ORBIT-AF)的结果
J Am Heart Assoc. 2015 May 21;4(5):e001901. doi: 10.1161/JAHA.115.001901.

引用本文的文献

1
Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapy.导管消融或抗心律失常药物治疗后与复发性心房颤动相关的临床和社会经济因素。
Heart Rhythm O2. 2025 Feb 21;6(5):631-640. doi: 10.1016/j.hroo.2025.02.007. eCollection 2025 May.
2
Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis.胰高血糖素样肽-1 受体激动剂对导管消融后心房颤动复发的影响:系统评价和荟萃分析。
Adv Ther. 2024 Oct;41(10):3749-3756. doi: 10.1007/s12325-024-02959-x. Epub 2024 Aug 14.
3
A randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (The SHAM-PVI study): Study design and rationale.一项针对症状性心房颤动(SHAM-PVI 研究)中肺静脉隔离的随机假手术对照研究:研究设计和原理。
Clin Cardiol. 2023 Aug;46(8):973-980. doi: 10.1002/clc.24066. Epub 2023 Jun 13.
4
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.房颤卒中预防的研究机遇:国家心肺血液研究所虚拟研讨会报告。
Stroke. 2023 Mar;54(3):e75-e85. doi: 10.1161/STROKEAHA.121.038273. Epub 2023 Feb 27.
5
Human assay for irreversible electroporation cardiac ablation.不可逆电穿孔心脏消融的人体试验。
Front Physiol. 2023 Jan 9;13:1064168. doi: 10.3389/fphys.2022.1064168. eCollection 2022.
6
Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report.将心房颤动研究转化为整合健康的社会决定因素:美国国立心肺血液研究所研讨会报告。
JAMA Cardiol. 2023 Feb 1;8(2):182-191. doi: 10.1001/jamacardio.2022.4091.
7
Dietary supplement use and documentation in a breast cancer survivorship clinic.乳腺癌生存者诊所中的膳食补充剂使用和记录情况。
Breast Cancer Res Treat. 2022 Jan;191(2):385-388. doi: 10.1007/s10549-021-06454-7. Epub 2021 Nov 24.
8
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report.心房颤动二级预防的研究重点:美国国立心肺血液研究所虚拟研讨会报告
J Am Heart Assoc. 2021 Aug 17;10(16):e021566. doi: 10.1161/JAHA.121.021566. Epub 2021 Aug 5.
9
A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (Real-AF): design and objectives.一项针对症状性阵发性和持续性心房颤动导管消融治疗的真实世界经验的前瞻性多中心注册研究(Real-AF):设计和目标。
J Interv Card Electrophysiol. 2021 Dec;62(3):487-494. doi: 10.1007/s10840-021-01031-w. Epub 2021 Jul 2.
10
Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study.中部分子氨基末端脑利钠肽前体和可溶性肿瘤抑制因子 2 水平对导管消融治疗心房颤动患者心律的影响:Biorhythm 研究。
J Am Heart Assoc. 2021 Jul 6;10(13):e020917. doi: 10.1161/JAHA.121.020917. Epub 2021 Jun 30.

本文引用的文献

1
Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure.心房颤动伴收缩性心力衰竭患者的消融治疗的荟萃分析
Cardiovasc Ther. 2019 Jan 6;2019:8181657. doi: 10.1155/2019/8181657. eCollection 2019.
2
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.导管消融与抗心律失常药物治疗对心房颤动患者死亡率、卒中和出血及心搏骤停的影响:CABANA 随机临床试验。
JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693.
3
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.导管消融与药物治疗对心房颤动患者生活质量的影响:CABANA 随机临床试验。
JAMA. 2019 Apr 2;321(13):1275-1285. doi: 10.1001/jama.2019.0692.
4
Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.《2019年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659.
5
Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging and Catheter Ablation of Atrial Fibrillation: 5-Year Follow-Up Data.延迟钆增强磁共振成像与导管消融治疗心房颤动相关性心房纤维化:5 年随访数据。
J Am Heart Assoc. 2018 Dec 4;7(23):e006313. doi: 10.1161/JAHA.117.006313.
6
Atrial Fibrillation Mechanisms and Implications for Catheter Ablation.心房颤动的机制及其对导管消融的影响。
Front Physiol. 2018 Oct 17;9:1458. doi: 10.3389/fphys.2018.01458. eCollection 2018.
7
Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice: Endorsed by the Heart Rhythm Society Board of Trustees.心房颤动患者登记处和临床实践中使用的协调结局指标:得到心律学会理事会的认可。
Heart Rhythm. 2019 Jan;16(1):e3-e16. doi: 10.1016/j.hrthm.2018.09.021. Epub 2018 Nov 16.
8
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study.基于应用程序的大型研究,使用智能手表识别心律失常的原理和设计:Apple Heart Study。
Am Heart J. 2019 Jan;207:66-75. doi: 10.1016/j.ahj.2018.09.002. Epub 2018 Sep 8.
9
Multimorbidity Burden and Adverse Outcomes in a Community-Based Cohort of Adults with Heart Failure.基于社区的心力衰竭成人队列中多重疾病负担与不良结局。
J Am Geriatr Soc. 2018 Dec;66(12):2305-2313. doi: 10.1111/jgs.15590. Epub 2018 Sep 24.
10
The Fibrotic Substrate in Persistent Atrial Fibrillation Patients: Comparison Between Predictions From Computational Modeling and Measurements From Focal Impulse and Rotor Mapping.持续性心房颤动患者的纤维化基质:计算建模预测与局灶性冲动和转子标测测量结果的比较
Front Physiol. 2018 Aug 29;9:1151. doi: 10.3389/fphys.2018.01151. eCollection 2018.

导管消融治疗心房颤动的研究需求和重点:来自美国国立心肺血液研究所虚拟研讨会的报告。

Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.

机构信息

Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.A., J.P.P.).

Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, and Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.).

出版信息

Circulation. 2020 Feb 11;141(6):482-492. doi: 10.1161/CIRCULATIONAHA.119.042706. Epub 2019 Nov 20.

DOI:10.1161/CIRCULATIONAHA.119.042706
PMID:31744331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7043236/
Abstract

Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ablation significantly reduced cardiovascular hospitalizations. Despite the existing data on AF catheter ablation, numerous knowledge gaps remain concerning this intervention. This report is based on a recent virtual workshop convened by the National Heart, Lung, and Blood Institute to identify key research opportunities in AF ablation. We outline knowledge gaps related to emerging technologies, the relationship between cardiac structure and function and the success of AF ablation in patient subgroups in whom clinical benefit from ablation varies, and potential platforms to advance clinical research in this area. This report also considers the potential value and challenges of a sham ablation randomized trial. Prioritized research opportunities are identified and highlighted to empower relevant stakeholders to collaborate in designing and conducting effective, cost-efficient, and transformative research to optimize the use and outcomes of AF ablation.

摘要

导管消融技术在心房颤动(房颤)患者的治疗中取得了重大进展。多项随机试验证明,房颤导管消融术可以降低房颤复发的风险,提高生活质量。在一些研究中,房颤消融术显著减少了心血管住院治疗。尽管有关于房颤导管消融术的现有数据,但对于这种干预措施仍存在许多知识空白。本报告基于美国国立心肺血液研究所最近召开的一次虚拟研讨会,旨在确定房颤消融术的关键研究机会。我们概述了与新兴技术、心脏结构和功能之间的关系以及在消融获益因患者亚组而异的情况下,房颤消融术成功相关的知识空白,以及推进该领域临床研究的潜在平台。本报告还考虑了假消融随机试验的潜在价值和挑战。确定了优先研究机会,并强调赋予相关利益攸关方权力,以合作设计和开展有效、具有成本效益和变革性的研究,优化房颤消融术的使用和结果。